DE3581921D1 - Synthetische polymere arzneistoffe. - Google Patents

Synthetische polymere arzneistoffe.

Info

Publication number
DE3581921D1
DE3581921D1 DE8585309560T DE3581921T DE3581921D1 DE 3581921 D1 DE3581921 D1 DE 3581921D1 DE 8585309560 T DE8585309560 T DE 8585309560T DE 3581921 T DE3581921 T DE 3581921T DE 3581921 D1 DE3581921 D1 DE 3581921D1
Authority
DE
Germany
Prior art keywords
peptide
mol
units derived
bound
methacryloylated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8585309560T
Other languages
English (en)
Inventor
Jindrich Kopecek
Pavla Rejmanova
Jiri Strohalm
Karel Ulbrich
Blanka Rihova
Vladimir Chytry
John B Lloyd
Ruth Duncan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Czech Academy of Sciences CAS
Cancer Research Campaign Technology Ltd
Original Assignee
Czech Academy of Sciences CAS
Cancer Research Campaign Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Czech Academy of Sciences CAS, Cancer Research Campaign Technology Ltd filed Critical Czech Academy of Sciences CAS
Application granted granted Critical
Publication of DE3581921D1 publication Critical patent/DE3581921D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/811—Peptides or proteins is immobilized on, or in, an inorganic carrier
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/815—Carrier is a synthetic polymer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/815—Carrier is a synthetic polymer
    • Y10S530/816—Attached to the carrier via a bridging agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
DE8585309560T 1985-01-04 1985-12-31 Synthetische polymere arzneistoffe. Expired - Lifetime DE3581921D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB858500209A GB8500209D0 (en) 1985-01-04 1985-01-04 Synthetic polymeric drugs

Publications (1)

Publication Number Publication Date
DE3581921D1 true DE3581921D1 (de) 1991-04-04

Family

ID=10572420

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8585309560T Expired - Lifetime DE3581921D1 (de) 1985-01-04 1985-12-31 Synthetische polymere arzneistoffe.

Country Status (9)

Country Link
US (1) US5037883A (de)
EP (1) EP0187547B1 (de)
JP (2) JPH075474B2 (de)
AT (1) ATE60991T1 (de)
AU (1) AU589587B2 (de)
CA (1) CA1305053C (de)
DE (1) DE3581921D1 (de)
DK (1) DK164485C (de)
GB (1) GB8500209D0 (de)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4738434A (en) 1986-04-07 1988-04-19 Marjoram Robert H Vibration and/or shock attenuating fluid mount or the like
JP2896580B2 (ja) * 1989-08-25 1999-05-31 チッソ株式会社 アミロース―リゾチームハイブリッドと活性化糖およびその製造法
DE69120141T2 (de) * 1990-03-28 1996-11-28 Shuji Kojima Polymerkombiniertes Arzneimittel zur Magenbehandlung und Verfahren zu dessen Herstellung
CA2046830C (en) 1990-07-19 1999-12-14 Patrick P. Deluca Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
CZ279785B6 (cs) * 1991-02-01 1995-06-14 Galena, A.S. Směrované polymerní konjugáty cyklosporinu
US5332575A (en) * 1991-10-03 1994-07-26 Parfums Christian Dior Method of targeting melanocytes with a compound containing a fucose residue
US5258453A (en) * 1992-01-21 1993-11-02 University Of Utah Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light
GB9213077D0 (en) * 1992-06-19 1992-08-05 Erba Carlo Spa Polymerbound taxol derivatives
GB2270920B (en) * 1992-09-25 1997-04-02 Univ Keele Alginate-bioactive agent conjugates
US7056935B2 (en) 1995-06-07 2006-06-06 Gpi Nil Holdings, Inc. Rotamase enzyme activity inhibitors
GB9600471D0 (en) * 1996-01-10 1996-03-13 Univ London Pharmacy Drug delivery system
GB9606975D0 (en) * 1996-04-02 1996-06-05 Univ Birmingham Anti-tumor agent
EP0895784B1 (de) 1996-04-15 2005-11-23 Asahi Kasei Kabushiki Kaisha Arzneimittelkomplexe enthaltend taxan-verbindungen oder steroiden
AU7124598A (en) * 1997-04-18 1998-11-13 Access Pharmaceuticals, Inc. Polymer-platinum compounds
US5965118A (en) * 1997-04-18 1999-10-12 Access Pharmaceuticals, Inc. Polymer-platinum compounds
US6251866B1 (en) 1997-08-05 2001-06-26 Watson Laboratories, Inc. Conjugates targeted to the interleukin-2 receptor
US6180084B1 (en) * 1998-08-25 2001-01-30 The Burnham Institute NGR receptor and methods of identifying tumor homing molecules that home to angiogenic vasculature using same
US6066673A (en) * 1998-03-12 2000-05-23 The Procter & Gamble Company Enzyme inhibitors
US7018654B2 (en) 1999-03-05 2006-03-28 New River Pharmaceuticals Inc. Pharmaceutical composition containing an active agent in an amino acid copolymer structure
US6716452B1 (en) 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US7060708B2 (en) 1999-03-10 2006-06-13 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
AU1820400A (en) * 1999-11-17 2001-05-30 School Of Pharmacy, University Of London, The Conjugates of hpma copolymer and ellipticin
CA2400953A1 (en) 2000-02-24 2001-08-30 Kopran Research Laboratories Limited Orally administrable acid stable anti-ulcer benzimidazole derivatives
AU2001288829A1 (en) 2000-09-06 2002-03-22 Ap Pharma, Inc. Degradable polyacetal polymers
US8394813B2 (en) 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
EP1401875A4 (de) * 2001-05-04 2005-01-26 Univ Utah Res Found Hyaluronsäure enthaltende biokonjugate: gezielte abgabe von antikrebsmitteln an krebszellen
US20060014697A1 (en) 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
US7375082B2 (en) 2002-02-22 2008-05-20 Shire Llc Abuse-resistant hydrocodone compounds
US7169752B2 (en) 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US7375083B2 (en) 2003-09-30 2008-05-20 Shire Llc Pharmaceutical compositions for prevention of overdose or abuse
WO2003017938A2 (en) * 2001-08-22 2003-03-06 Watson Pharmaceuticals, Inc. Conjugates targeted to target receptors
US7338939B2 (en) 2003-09-30 2008-03-04 New River Pharmaceuticals Inc. Abuse-resistant hydrocodone compounds
CZ293787B6 (cs) * 2001-12-20 2004-07-14 Zentiva, A.S. pH senzitivní polymerní konjugáty antracyklinového kancerostatika pro cílenou terapii
US7105486B2 (en) 2002-02-22 2006-09-12 New River Pharmaceuticals Inc. Abuse-resistant amphetamine compounds
US7659253B2 (en) 2002-02-22 2010-02-09 Shire Llc Abuse-resistant amphetamine prodrugs
IL163667A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Novel sustained release pharmaceutical compounds to preventabuse of controlled substances
US7700561B2 (en) 2002-02-22 2010-04-20 Shire Llc Abuse-resistant amphetamine prodrugs
AU2003226349B2 (en) * 2002-04-11 2008-01-31 Children's Medical Center Corporation Methods for inhibiting vascular hyperpermeability
CA2480666C (en) * 2002-04-11 2012-03-06 Children's Medical Center Corporation Tnp-470 polymer conjugates and use thereof
CA2483696A1 (en) * 2002-05-06 2003-11-20 University Of Utah Research Foundation Preblocking with non-ha gags increases effectiveness of ha conjugated anticancer agents
US20040116348A1 (en) * 2002-09-23 2004-06-17 Ying Chau Polymer-linker-drug conjugates for targeted drug delivery
US8133881B2 (en) 2003-01-13 2012-03-13 Shire Llc Carbohydrate conjugates to prevent abuse of controlled substances
US20060099265A1 (en) * 2003-03-20 2006-05-11 Kazuhisa Shimizu Micellar preparation containing sparingly water-soluble anticancer agent and novel block copolymer
DE602004025799D1 (de) 2003-04-15 2010-04-15 Glaxosmithkline Llc Humane il-18 substitutionsmutanten und deren konjugate
KR101159477B1 (ko) 2003-05-29 2012-07-02 샤이어 엘엘씨 남용 방지성 암페타민 화합물
BR122018071808B8 (pt) * 2003-11-06 2020-06-30 Seattle Genetics Inc conjugado
US10092662B2 (en) * 2004-03-31 2018-10-09 University Of Utah Research Foundation Macromolecular delivery systems for non-invasive imaging, evaluation and treatment of arthritis and other inflammatory diseases
EP1792927B1 (de) 2004-09-22 2013-03-06 Nippon Kayaku Kabushiki Kaisha Neues blockcopolymer, micellenzubereitung und antikrebsmittel, das diese als wirkbestandteil enthält
CN101106974B (zh) 2005-01-14 2012-08-08 韩国科学技术研究院 形成自聚集体的胆甾烷酸-脱乙酰壳多糖复合物及其制备方法
US20080248030A1 (en) * 2005-02-02 2008-10-09 Children's Medical Center Corporation Method of Treating Angiogenic Diseases
WO2007111211A1 (ja) 2006-03-28 2007-10-04 Nippon Kayaku Kabushiki Kaisha タキサン類の高分子結合体
JP5181347B2 (ja) 2006-05-18 2013-04-10 日本化薬株式会社 ポドフィロトキシン類の高分子結合体
WO2007143209A2 (en) * 2006-06-02 2007-12-13 University Of Virginia Patent Foundation Luminescent diketonate polymers
JP5548364B2 (ja) * 2006-10-03 2014-07-16 日本化薬株式会社 レゾルシノール誘導体の高分子結合体
US8334364B2 (en) 2006-11-06 2012-12-18 Nipon Kayaku Kabushiki Kaisha High-molecular weight derivative of nucleic acid antimetabolite
WO2008056654A1 (en) 2006-11-08 2008-05-15 Nippon Kayaku Kabushiki Kaisha Polymeric derivative of nucleic acid metabolic antagonist
CN1973902B (zh) * 2006-12-12 2010-11-10 东北师范大学 以人参多糖为载体的抗肿瘤药物阿霉素复合物及制备方法
USRE46190E1 (en) 2007-09-28 2016-11-01 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of steroids
KR101589582B1 (ko) * 2008-03-18 2016-01-28 니폰 가야꾸 가부시끼가이샤 생리활성물질의 고분자량 결합체
US9149540B2 (en) 2008-05-08 2015-10-06 Nippon Kayaku Kabushiki Kaisha Polymer conjugate of folic acid or folic acid derivative
BRPI0920655A2 (pt) * 2008-10-07 2019-07-09 Rexahn Pharmaceuticals Inc conjugados e hpma-docetaxel ou gencitabina e usos dos mesmos
JP5544357B2 (ja) 2009-05-15 2014-07-09 日本化薬株式会社 水酸基を有する生理活性物質の高分子結合体
EP2488207A4 (de) 2009-10-13 2015-06-10 Rexahn Pharmaceuticals Inc Polymere systeme zur freisetzung von antikrebsmitteln
CZ302830B6 (cs) * 2009-12-15 2011-11-30 Ústav makromolekulární chemie AV CR, v.v.i. Vysokomolekulární polymerní nosice léciv odvozené od dendrimeru a jejich konjugáty s lécivy pro lécbu zejména pevných nádoru
WO2011112482A2 (en) 2010-03-08 2011-09-15 University Of Utah Research Foundation Polymeric drug delivery conjugates and methods of making and using thereof
CN107141410B (zh) 2010-05-25 2022-12-09 辛德弗雷克斯公司 聚合物缀合的MetAP2抑制剂及其应用的治疗方法
US9895449B2 (en) 2010-05-25 2018-02-20 Syndevrx, Inc. Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof
WO2012067138A1 (ja) 2010-11-17 2012-05-24 日本化薬株式会社 新規なシチジン系代謝拮抗剤の高分子誘導体
DK2683393T3 (en) 2011-02-11 2018-07-23 Univ Michigan Regents TRIPEPTIME COMPOSITIONS AND THEIR USE IN TREATING DIABETES
US9346923B2 (en) 2011-09-11 2016-05-24 Nippon Kayaku Kabushiki Kaisha Method for manufacturing block copolymer
WO2014164913A1 (en) 2013-03-12 2014-10-09 University Of Utah Research Foundation Compositions and methods for inducing apoptosis
AU2014250983B2 (en) * 2013-04-10 2019-04-11 Syndevrx, Inc. MetAP2 inhibitors and methods of treating obesity
CN103965398B (zh) * 2014-04-11 2016-04-13 西北师范大学 D-半乳糖/苯甲醛氮芥/n-(2-羟丙基)甲基丙烯酰胺共聚物及其制备和应用
WO2017100553A1 (en) 2015-12-10 2017-06-15 Syndevrx, Inc. Fumagillol derivatives and polymorphs thereof
CN108697807B (zh) 2016-01-11 2021-11-26 辛德弗雷克斯公司 代谢功能障碍引起的肿瘤的治疗
EP3555280A4 (de) 2016-12-19 2020-09-09 The Regents of The University of California Auf duales enzym reagierende peptide
US11541125B2 (en) 2016-12-19 2023-01-03 The Regents Of The University Of California Noncrushable pill formulations
CA3060243A1 (en) 2017-04-17 2018-10-25 The University Of Chicago Polymer materials for delivery of short-chain fatty acids to the intestine for applications in human health and treatment of disease
US10894019B2 (en) 2017-08-15 2021-01-19 University Of South Carolina Drug delivery system and method for targeting cancer stem cells
AU2019366819A1 (en) 2018-10-26 2021-06-03 Syndevrx Inc. Biomarkers of MetAP2 inhibitors and applications thereof
US11672767B2 (en) 2019-05-13 2023-06-13 University Of South Carolina Enzymatically cleavable self-assembled nanoparticles for morphogen delivery

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL133221C (de) * 1965-11-12
US3957700A (en) * 1972-05-04 1976-05-18 British Industrial Plastics Limited Filled aminoplast moulding materials
US4007142A (en) * 1974-04-24 1977-02-08 Balm Paints Limited Amine resin and process
GB8311136D0 (en) * 1983-04-25 1983-06-02 Lepetit Spa Immobilised oligopeptides

Also Published As

Publication number Publication date
ATE60991T1 (de) 1991-03-15
DK3386D0 (da) 1986-01-03
EP0187547A3 (en) 1987-07-22
DK3386A (da) 1986-07-05
EP0187547A2 (de) 1986-07-16
JPS61243026A (ja) 1986-10-29
CA1305053C (en) 1992-07-14
GB8500209D0 (en) 1985-02-13
DK164485C (da) 1992-11-23
AU589587B2 (en) 1989-10-19
EP0187547B1 (de) 1991-02-27
AU5183386A (en) 1986-07-10
JP2620517B2 (ja) 1997-06-18
DK164485B (da) 1992-07-06
JPH07300428A (ja) 1995-11-14
JPH075474B2 (ja) 1995-01-25
US5037883A (en) 1991-08-06

Similar Documents

Publication Publication Date Title
DE3581921D1 (de) Synthetische polymere arzneistoffe.
WO1997025067A3 (en) Polymers
DE69431185T2 (de) Erweiterung des vitamin b 12 - aufnahmesystems unter verwendung von polymeren
BR9713486A (pt) Preparações farmacêuticas compreendidas de sais de ácido hialurÈnico com anestésicosm locais.
DE3650753D1 (de) Auf einmaligen sequenzen innerhalb des veränderlichen gebiets des t-zellrezeptors basierte diagnosemittel und deren verwendung
EP1518550A3 (de) Bioadhäsive Darreichungssysteme mit Poly(fumarsäure-co-sebacinsäure)
FR2402662A1 (fr) Polymeres contenant des groupes imidyles et silyles, utilisables notamment comme adjuvants d'adherence
DE69334350D1 (de) P- Selectin Ligandenprotein
IT1249045B (it) Processo per la sintesi allo stato solido di polimeri dell'acido lattico e prodotti cosi ottenuti
PT998501E (pt) Polimeros cationicos complexos associando os referidos polimeros cationicos e substancias terapeuticamente activas compreendendo pelo menos uma carga negativa especialmente acidos nucleicos e sua utilizacao em terapia genica
ATE290564T1 (de) Funktionsfähige poly-alpha-aminosäurederivate zur modifizierung von biologisch wirksamen stoffen und deren herstellung
ES2111653T3 (es) Gen que codifica la heparinasa de flavobacterium heparinum.
ES2052554T3 (es) Poliaminas polimeras.
DE3678640D1 (de) Geschmack abdeckende zusammensetzungen.
DE3687238D1 (de) Polyamidharze.
ITMI911950A1 (it) Sistema terapeutico transdermale per la somministrazione di farmaci ad attivita' broncodilatante.
MY113340A (en) Oral administration from having acid active substances and a process for its production
GB2324534A (en) Polymers
DE68909451D1 (de) Peptide mit inhibitorischer wirkung auf enzymatische systeme, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
SCHOTMAN Reaction of isocyanates with carboxylic acids and its application to polymer synthesis(Ph. D. Thesis)
TH2661EX (th) น้ำยาดัดผมสำหรับดัดโดยใช้ความร้อนและกรรมวิธีในการดัดผม
IT8830617V0 (it) Sistema completo per iniezione costituito da siringa, ago, disinfettante ed eventuale supporto, in unica confezione.
ATE75485T1 (de) Biologisch aktive peptide, deren verfahren zur herstellung und pharmazeutische zusammensetzungen.
TH19871A (th) ซับสทิทิวเทดเบนแซมิดีน การเตรียมและการใช้สารเหล่านี้เป็นสารเภสัชกรรม

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee